Literature DB >> 19144868

Ovarian cancer and genetic susceptibility: association of A61G polymorphism in the EGF gene.

Ana Paula Araújo1, Ricardo Ribeiro, Deolinda Pereira, Daniela Pinto, Berta Sousa, Raquel Catarino, Rui Medeiros.   

Abstract

Growth factors play an essential role in regulating cellular proliferation, and lack of control is characteristic of malignant development. The epidermal growth factor (EGF) gene codifies a growth factor that binds to the EGF receptor (EGFR), which is involved in activating pathways that promote cellular proliferation, survival, migration and differentiation. The purpose of this study was to appraise the association between EGF gene A61G polymorphism with ovarian cancer susceptibility. A total of 564 DNA samples were analysed from 175 women with ovarian cancer and 389 women without cancer, through PCR-RFLP. We found a decreased risk for developing ovarian cancer in GG carriers compared to AA carriers (OR = 0.46, CI = 0.25-0.83, P = 0.010). The seemingly protective role in GG carriers was observed in women under 53 years of age (OR = 0.38, CI = 0.16-0.86, P = 0.011) and in patients diagnosed with advanced stage disease (OR = 0.38, CI = 0.18-0.81, P = 0.012). Allelic comparison evidenced similar results, with decreased risk for G allele. We further observed a linear trend for G allele in cancer risk. Moreover, we analysed the influence of genotypes in the time to onset of the disease and observed that GG carriers had ovarian cancer later than AA carriers (P = 0.035). We hypothesize that this polymorphism confers protection for ovarian cancer development.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19144868     DOI: 10.3181/0805-RM-146

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  8 in total

1.  Association between EGF +61A/G polymorphism and gastric cancer in Caucasians.

Authors:  Ana Paula Araújo; Bruno M Costa; Ana L Pinto-Correia; Maria Fragoso; Paula Ferreira; Mário Dinis-Ribeiro; Sandra Costa; Rui M Reis; Rui Medeiros
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

2.  Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer.

Authors:  Chan H Han; Qingyi Wei; Karen K Lu; Zhensheng Liu; Gordon B Mills; Li-E Wang
Journal:  Int J Clin Exp Med       Date:  2009-10-31

3.  Association between EGF +61 G/A and glioma risk in a Chinese population.

Authors:  Shujie Wang; Yao Zhao; Zhenchao Ruan; Hongyan Chen; Weiwei Fan; Juxiang Chen; Qihan Wu; Ji Qian; Tianbao Zhang; Yan Huang; Daru Lu
Journal:  BMC Cancer       Date:  2010-05-21       Impact factor: 4.430

4.  EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis.

Authors:  Rebecca A Mason; Elaine V Morlock; Margaret R Karagas; Karl T Kelsey; Carmen J Marsit; Alan R Schned; Angeline S Andrew
Journal:  Carcinogenesis       Date:  2009-04-16       Impact factor: 4.944

Review 5.  Epidermal growth factor, from gene organization to bedside.

Authors:  Fenghua Zeng; Raymond C Harris
Journal:  Semin Cell Dev Biol       Date:  2014-02-07       Impact factor: 7.727

6.  Association between EGF promoter polymorphisms and cancer risk: a meta-analysis.

Authors:  Wei Xu; Yan Li; Xueli Wang; Bo Chen; Shan Liu; Yan Wang; Weihong Zhao; Jianqing Wu
Journal:  Med Oncol       Date:  2009-12-24       Impact factor: 3.064

7.  Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma.

Authors:  Hal W Hirte
Journal:  Onco Targets Ther       Date:  2013-04-18       Impact factor: 4.147

8.  Different frequency of epidermal growth factor rs76189946 polymorphism genotype in an Iranian colorectal cancer.

Authors:  Vahid Chaleshi; Sanaz Savabkar; Hesamodin Dolatmoradi; Mahdi Montazer Haghighi; Elmira Khalili Maryan; Sara Pasha; Narges Ebrahimi Vandfaez; Ehsan Nazemalhosseini Mojarad; Hamid Asadzadeh Aghdaei; Mohammad Reza Zali
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2013
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.